Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-08
  • 2025-07
  • 2025-06
  • Gastrin I (human): Unveiling CCK2 Signaling in Next-Gen G...

    2026-02-12

    Gastrin I (human): Unveiling CCK2 Signaling in Next-Generation Gastrointestinal Models

    Introduction: Redefining Gastrointestinal Research with Gastrin I (human)

    Gastric acid secretion is a cornerstone of human gastrointestinal (GI) physiology, tightly regulated by an intricate network of hormones, receptors, and cellular pathways. Among these, Gastrin I (human)—an endogenous peptide—stands out as both a fundamental regulator and a powerful experimental tool. As research transitions toward more physiologically relevant models, notably those derived from human pluripotent stem cells, the demand for high-purity, functionally validated peptides such as Gastrin I (human) (SKU: B5358) has become paramount. This article explores the mechanistic depth, advanced applications, and future potential of Gastrin I (human) in CCK2 receptor signaling and GI pathway research, uniquely integrating concepts from recent breakthroughs in organoid technology and drug metabolism studies.

    Molecular Characteristics and Biochemical Properties

    Gastrin I (human) is a 17-amino acid regulatory peptide (CAS: 10047-33-3) with a molecular weight of 2098.22 Da. It is supplied by APExBIO as a high-purity (≥98% by HPLC and mass spectrometry) white lyophilized solid. Insoluble in water and ethanol but readily soluble in DMSO (≥21 mg/mL), its handling and storage (desiccated at -20°C) ensure optimal experimental fidelity. These biochemical properties facilitate its reliable use in gastric acid secretion pathway research and receptor-mediated signal transduction assays, underscoring its value in gastrointestinal physiology studies.

    Mechanism of Action: CCK2 Receptor Signaling and Proton Pump Activation

    Gastrin I as a CCK2 Receptor Agonist

    Functionally, Gastrin I (human) operates as a potent CCK2 receptor agonist. By binding specifically to the cholecystokinin B (CCK2) receptors predominantly expressed on gastric parietal cells, it triggers a cascade of intracellular events. This binding promotes phospholipase C activation, leading to increased intracellular calcium and subsequent stimulation of H+/K+-ATPase activity—the proton pump responsible for acid secretion. The net result is a marked elevation in gastric acid output, providing a robust and controllable model for dissecting proton pump activation and downstream signaling pathways.

    Receptor-Mediated Signal Transduction in GI Physiology

    This receptor-mediated mechanism is central not only to normal digestive function but also to the pathogenesis of various GI disorders. By experimentally manipulating Gastrin I levels, researchers can interrogate subtle aspects of CCK2 receptor signaling, receptor desensitization, feedback inhibition, and the interplay with other GI hormones. The peptide's high specificity and purity minimize confounding variables—critical for mechanistic studies and pharmacological screening.

    Comparative Analysis: Gastrin I (human) Versus Alternative Methods

    Historically, studies of gastric acid secretion and GI signaling have relied on animal models or immortalized cell lines such as Caco-2. While invaluable, these models introduce species-specific differences and limited expression of key metabolic enzymes, as highlighted in the seminal work by Saito et al. (2025). The authors demonstrated that conventional models often fail to recapitulate the complex, integrative physiology of the human intestine—particularly in response to regulatory peptides like Gastrin I.

    In contrast, the use of Gastrin I (human) in advanced systems, including human pluripotent stem cell-derived organoids, enables nuanced exploration of human-specific pathways. Unlike prior articles that primarily focus on practical workflows or protocol optimization (see Costunolide's guide), this piece delves into the limitations of legacy models and how state-of-the-art reagents are redefining research possibilities.

    Advanced Applications: Human Intestinal Organoids and Pharmacokinetic Modeling

    Organoid Technology: Bridging the Translational Gap

    The advent of human induced pluripotent stem cell (hiPSC)-derived intestinal organoids (IOs) represents a paradigm shift in GI research. As Saito et al. show, these 3D culture-derived IOs closely mimic the cellular diversity, architecture, and functional attributes of the human intestine, including cytochrome P450 metabolism and transporter expression. When seeded on 2D monolayers, IOs give rise to mature enterocytes, goblet cells, and enteroendocrine populations—providing a near-physiological context for drug and hormone studies.

    Within this framework, Gastrin I (human) is invaluable for probing GI hormone receptor interactions, dissecting gastric acid secretion regulator pathways, and modeling disease states such as hypergastrinemia or atrophic gastritis. Its use in hiPSC-derived systems overcomes the limitations of Caco-2 cells (which lack robust CYP3A4 activity) and murine models (which differ in hormone receptor profiles), as detailed in the reference study.

    Elucidating CCK2 Receptor Signaling in Human Contexts

    Deploying Gastrin I in these advanced models supports rigorous investigation into CCK2 receptor pharmacodynamics, the modulation of acid secretion by therapeutic agents, and the interaction with epithelial stem cell niches. These applications extend beyond traditional assay development, enabling precise mapping of signaling networks and drug response variability—areas that existing articles, such as America Peptides' overview, have touched upon but not thoroughly dissected at the mechanistic and translational interface.

    Gastrin I (human) in Gastrointestinal Disorder Research

    Aberrant Gastrin-CCK2 signaling is implicated in a spectrum of GI pathologies, including Zollinger-Ellison syndrome, peptic ulcer disease, and certain gastric neoplasms. By leveraging hiPSC-derived organoids and APExBIO's high-purity Gastrin I (human), researchers can create disease-relevant models to:

    • Evaluate the efficacy and specificity of proton pump inhibitors and CCK2 antagonists
    • Study compensatory mechanisms in acid secretion regulation
    • Assess the impact of chronic hypergastrinemia on epithelial proliferation and transformation

    This deepens our understanding beyond what is covered in translational reviews, such as the thought-leadership article at GW-786034, by integrating organoid biology and patient-specific modeling with peptide pharmacology.

    Quality, Handling, and Experimental Considerations

    Optimal experimental outcomes hinge on reagent quality and precise handling. Gastrin I (human) from APExBIO is supplied at ≥98% purity, with batch-specific HPLC and mass spectrometry validation. The lyophilized peptide is stable when stored desiccated at -20°C. Reconstitute only with DMSO (≥21 mg/mL); avoid water or ethanol. Due to its instability in solution, prepare working aliquots immediately before use, and avoid long-term storage of solutions. These stringent quality controls and handling practices ensure reproducibility in sensitive applications such as gastric acid secretion pathway research, receptor signaling assays, and gastrointestinal disorder research.

    Comparative Content Hierarchy: Building on Existing Knowledge

    While prior articles have explored protocol optimization (Costunolide), workflow reproducibility, and the practical value of high-purity peptides, this article uniquely integrates mechanistic insights from stem cell biology, organoid modeling, and advanced pharmacokinetic research. For instance, the ASC-J9 feature highlights CCK2 agonism in organoid systems, but our analysis delves deeper into translational applications, the limitations of legacy models, and the experimental nuances required for next-generation GI studies.

    Conclusion and Future Outlook

    As the GI research landscape evolves, the intersection of high-fidelity biological models and rigorously characterized reagents is transforming both fundamental and translational science. Gastrin I (human)—particularly when sourced from APExBIO—remains an indispensable tool for gastrointestinal physiology studies, gastric acid secretion pathway research, and the elucidation of CCK2 receptor signaling in human-relevant contexts. By harnessing the synergy between advanced organoid systems and peptide pharmacology, researchers are poised to unravel complex disease mechanisms, accelerate drug discovery, and personalize therapeutic interventions in GI health.